HomeAGIO • NASDAQ
add
Agios Pharmaceuticals Inc
Previous close
$28.43
Day range
$27.84 - $29.46
Year range
$22.24 - $62.45
Market cap
1.58B USD
Avg Volume
1.70M
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
In the news
Financials
Income Statement
Revenue
Net income
| (USD) | Sep 2025info | Y/Y change |
|---|---|---|
Revenue | 12.88M | 43.69% |
Operating expense | 41.27M | 7.10% |
Net income | -103.43M | -110.91% |
Net profit margin | -803.05 | -107.59% |
Earnings per share | -1.78 | -21.49% |
EBITDA | -115.50M | -13.83% |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Sep 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 952.86M | -5.17% |
Total assets | 1.39B | -22.66% |
Total liabilities | 101.38M | -38.61% |
Total equity | 1.28B | — |
Shares outstanding | 58.31M | — |
Price to book | 1.29 | — |
Return on assets | -20.45% | — |
Return on capital | -21.27% | — |
Cash Flow
Net change in cash
| (USD) | Sep 2025info | Y/Y change |
|---|---|---|
Net income | -103.43M | -110.91% |
Cash from operations | -88.15M | -4.67% |
Cash from investing | 95.56M | -61.90% |
Cash from financing | 4.44M | 68.18% |
Net change in cash | 11.84M | -93.00% |
Free cash flow | -56.62M | -1,769.96% |
About
Agios Pharmaceuticals Inc. is a publicly trading American pharmaceutical company pioneering therapies for genetically defined diseases, with a near-term focus on developing therapies for hemolytic anemias. The company was founded in 2008 by Lewis Cantley, Tak Mak and Craig Thompson. Agios is a Delaware corporation headquartered in Cambridge, Massachusetts. The company tendered an initial public offering in July 2013. Wikipedia
Founded
2008
Website
Employees
487
